Resistance mutation info of target
Target General Information | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Target ID | T56418 | ||||||||||||||||||||||
Target Name | ALK tyrosine kinase receptor (ALK) | ||||||||||||||||||||||
Gene Name | ALK | ||||||||||||||||||||||
Species | Homo sapiens | ||||||||||||||||||||||
UniProt ID | ALK_HUMAN | ||||||||||||||||||||||
Sequence |
MGAIGLLWLLPLLLSTAAVGSGMGTGQRAGSPAAGPPLQPREPLSYSRLQRKSLAVDFVV PSLFRVYARDLLLPPSSSELKAGRPEARGSLALDCAPLLRLLGPAPGVSWTAGSPAPAEA RTLSRVLKGGSVRKLRRAKQLVLELGEEAILEGCVGPPGEAAVGLLQFNLSELFSWWIRQ GEGRLRIRLMPEKKASEVGREGRLSAAIRASQPRLLFQIFGTGHSSLESPTNMPSPSPDY FTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQ MDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGR YIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFF ALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYC NFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFP APIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPL LDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNP NKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPL KGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGE DACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLII AAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGA TGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFIS PLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVS CIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKL SKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPN DPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMA GGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCP GPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLW EIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIIL ERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAA PPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPT SLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPS SLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQPGP [Homo sapiens] |
||||||||||||||||||||||
Drug and Corresponding Resistance Mutations | |||||||||||||||||||||||
Mutation Info | Missense: C1156Y | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: F1174C | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: F1174L | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: F1174V | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Mutation Info | Missense: G1123S | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: G1202R | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||
Mutation Info | Missense: G1269A | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Mutation Info | Missense: I1171N | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: I1171S | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: I1171T | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Mutation Info | Missense: L1152R | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: L1196M | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
Mutation Info | Missense: S1206Y | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
Mutation Info | Missense: V1180L | ||||||||||||||||||||||
Drugs |
|
||||||||||||||||||||||
References | |||||||||||||||||||||||
REF 1 | Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. | ||||||||||||||||||||||
REF 2 | Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014 Nov 15;20(22):5686-96. | ||||||||||||||||||||||
REF 3 | Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013 Dec;45(12):1446-51. | ||||||||||||||||||||||
REF 4 | Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. PLoS One. 2016 Apr 5;11(4):e0153065. | ||||||||||||||||||||||
REF 5 | Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014 Apr;9(4):549-53. | ||||||||||||||||||||||
REF 6 | Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol. 2014 Dec;9(12):e86-7. | ||||||||||||||||||||||
REF 7 | The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun;4(6):662-673. | ||||||||||||||||||||||
REF 8 | Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. J Thorac Oncol. 2015 Jul;10(7):e55-7. | ||||||||||||||||||||||
REF 9 | Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 2014 Dec;9(12):1821-5. | ||||||||||||||||||||||
REF 10 | ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer. 2016 Jan;91:70-2. | ||||||||||||||||||||||
REF 11 | Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 Sep;17(5):e77-e94. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.